Literature DB >> 33178388

Effects of ATP9A on Extracellular Vesicle Release and Exosomal Lipid Composition.

Xiao Xu1,2, Limei Xu1,2, Peng Zhang2, Kan Ouyang1, Yin Xiao3, Jianyi Xiong1, Daping Wang1, Yujie Liang4, Li Duan1.   

Abstract

Numerous biological processes are regulated by the intercellular communications arising from extracellular vesicles (EVs) released from cells. However, the mechanisms that regulate the quantity of EV discharged have yet to be understood. While it is known that ATP9A, a P4-ATPase, is involved in endosomal recycling, it is not clear whether it also contributes to the release of EVs and the makeup of exosomal lipids. This study is aimed at exploring the role of human ATP9A in the process of EV release and, further, to analyze the profiles of EV lipids regulated by ATP9A. Our results demonstrate that ATP9A is located in both the intracellular compartments and the plasma membrane. The percentage of ceramides and sphingosine was found to be significantly greater in the control cells than in the ATP9A overexpression and ATP9A knockout groups. However, EV release was greater in ATP9A knockout cells, indicating that ATP9A inhibits the release of EVs. This study revealed the effects of ATP9A on the release of EVs and the lipid composition of exosomes.
Copyright © 2020 Xiao Xu et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33178388      PMCID: PMC7647784          DOI: 10.1155/2020/8865499

Source DB:  PubMed          Journal:  Oxid Med Cell Longev        ISSN: 1942-0994            Impact factor:   6.543


1. Introduction

As extracellular vesicles (EVs) released from cells are mediators of intercellular communications, they can transmit information between cells and are involved in tissue development and disease progression [1, 2]. EVs are categorized according to diameter, which ranges from 50 to 1000 nm. Based on the formation of EVs, they are categorized as either ectosomes or exosomes [3]. Ectosomes are created directly by the plasma membrane forming outward buds. Exosomes, however, are combination products of multivesicular endosomes (MVEs) fusing with the plasma membrane which are then discharged into extracellular space [4, 5]. One distinctive characteristic of eukaryotic cells is the composition of phospholipids in the plasma membrane, which are not distributed symmetrically. This has long been recognized as a potential influence on the release of vesicles. The distribution of phospholipid species differs in the two leaflets of biological membranes. The leaflet exposed to cytosol consists of phosphatidylserine (PS) and phosphatidylethanolamine (PE), whereas the exoplasmic leaflet contains mostly phosphatidylcholine (PC) and sphingomyelin [6]. This asymmetric phospholipid distribution is an important aspect in numerous diseases, such as cancer, cardiovascular disease, hepatic steatosis, and metabolic disorders. The asymmetric distribution is also involved in many physiological processes, including apoptosis, blood coagulation, apoptosis, cell signaling, cell and organelle morphology, host-virus interactions, intracellular vesicle trafficking, membrane permeability and stability, and regulation of membrane proteins [7, 8]. Usually, ATP-dependent lipid transporters are responsible for maintaining homeostasis of the phospholipid distribution; however, PS can be redistributed to the exoplasmic leaflet in response to pathophysiological conditions. This has been observed in platelet activation, in exosome release from tumor tissues, and in the majority of immune cell types, such as activated B cells, bone marrow-derived monocytes, dendritic cells, and macrophages [9]. The asymmetry of lipids is maintained actively by a variety of transporter families [10, 11]. One particular family is the P-type ATPase family, and the members of its largest subfamily, P4-ATPase, are known as flippases [7, 12]. These ATP-dependent enzymes relocate certain phospholipids away from the membrane's outer leaflet and toward the inner leaflet. This maintains the membrane's lipid asymmetry, which has been highlighted previously to be critical to several cellular processes. Mounting evidence indicates that in eukaryotic cells, P4-ATPases play a key role in the biogenesis of the transport vesicles involved in the biosynthetic and endocytic pathways [11]. Models characterizing the role of P4-ATPases in lipid translocation pathways have been informed by site-directed mutagenesis and structural modeling studies [13, 14]; however, the fundamental features of the transport pathway, the electrogenic properties of the flippases, and the mechanisms by which flipping occurs remain unclear. Using TAT-5, the P4-ATPase of Caenorhabditis elegans, Wehman et al. showed that the enzyme was involved in the release of EVs and maintenance of PE asymmetry [15]. Whereas, human ATP9A and ATP9B, which are orthologous to TAT-5, are primarily found inside intracellular compartments [16]. ATP9A is recognized as a regulator for endosomal recycling [17]; whether it contributes to EV release and the lipid profiles of exosomes has not yet been determined. It is well-known that during cell division, fusion, and death, cells regulate PE asymmetry and EV release [18]. Therefore, we hypothesized that ATP9 is involved in plasma membrane biosynthesis, cell outward budding, and EV release. This study examines the effects of ATP9A on the composition of exosomal lipids and the release of EVs in a human embryonic kidney 293 (HEK293) cell line.

2. Materials and Methods

2.1. Cell Culture

DMEM medium (DMEM; Life Technologies) plus 10% fetal bovine serum (FBS, Gibco) supplement was used to sustain the HEK293 cell line at 37°C and 5% CO2. Synovial fluid-derived human mesenchymal stem cells (SF-MSCs) were cultured in MesenGro Chemically Defined Medium.

2.2. Overexpression of ATP9A

Control for this study was provided by the lentivirus empty vector, pLenti-C-RFP, which does not contain any human genes. The 293T cells were variously transfected with pLenti-C-RFP, pMD2.G, and psPAX2. After 48 h, lentivirus was harvested and used to infect MSCs, followed by puromycin selection (used as plv-NC group). The whole length of the ATP9A gene was subcloned into the destination pLenti-C-RFP plasmids. pLenti ATP9A-RFP plasmids were then cotransfected into HEK293T cells along with psPAX2 and pMD2.G packaging vectors. Lentivirus particles released from HEK293T cells were harvested and filtered and then used to infect MSCs. Puromycin was used to select cells expressing ATP9A-OV.

2.3. ATP9A Knockout

The lentiCRISPRv2 plasmid was used, as this vector expresses Cas9 nuclease and inserts ATP9A-specific single-guide RNA (sgRNA) simultaneously [19]. The online tool CRISPR DESIGN (https://CRISPR.mit.edu) was used to design sgRNA. The oligo sequence 5′-AGGAGATCCGATGCTACGTG-3′ was created and then annealed before subcloning into lentiCRISPRv2. To produce the lentivirus, cloned lenti-CRISPRv2 sgATP9A plasmids were transferred into HEK293T cells with packaging plasmids pMD2.G and psPAX2 using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). MSCs were infected with purified lentivirus, and a monoclonal cell line was selected using puromycin.

2.4. Confocal Microscopy

Cells were stably infected with lentivirus ATP9A-RFP on a 35 mm confocal dish at 37°C. After 48 h, cells were washed twice with PBS. To fix the cells, 4% paraformaldehyde was used. DAPI-containing mounting medium was used to mount the cells. Using a 60x oil objective, an LSM 800 confocal laser scanning microscope (Carl Zeiss) was used to collect images. The device was equipped with DAPI (405 nm) and red (568 nm) lasers.

2.5. Quantification of EVs in Culture Medium

To detect and analyze the concentrations and sizes of exosomes, NanoSight N3000 (Malvern, Ltd., Malvern, UK) nanoparticle tracking analysis (NTA) was used. The measuring duration was 60 s, and parameters were applied according to the manufacturer's instructions. The EVs were diluted to 1 ml with PBS; the NTA 3.2 software (version 3.2.16) calculated exosome distribution and size [20].

2.6. Purification of Exosomes

To remove apoptotic cell bodies and cellular debris, the medium (20 ml) was centrifuged at 200 G for 10 min, and then again at 2,000 G for 20 min. To remove macrovesicles, the supernatant was ultracentrifuged at 10,000 G for 25 min. Ultracentrifugation was used at 100,000 G for 60 min to retrieve exosomes. Exosome pellets were washed once with PBS, then centrifuged again at 100,000 G for 60 min. The resultant pellets were resuspended in 500 μl PBS. A Bradford assay was conducted to determine the concentration of protein. Western blotting was performed to detect exosome marker CD9, tumor susceptibility gene 101 (TSG101), Alix, and endoplasmic reticulum (ER) marker calnexin.

2.7. Metabolite Extraction and Lipidomics

A solution of exosome pellets in chloroform/methanol/water (2/1/1, v/v/v) was vortexed for 1 min then centrifuged for 10 min at 3000 G. The organic phage was harvested and transferred to a fresh tube, and nitrogen was used to lyophilize the phage. Isopropanol/methanol (1/1, v/v) solution (400 μl) was used to reconstitute dried metabolites. These were then vortexed and centrifuged at 10,000 G for 5 min at 4°C. LC-MS and a Kinetex C18 column (100 × 2.1 mm, 1.9 μm) were used to analyze supernatant. The flow rate was set at 0.4 ml/min. Lipidomic assays in positive mode and negative mode were conducted following the protocol described in a previous report [21]. Lipid Search v 4.0.20 software (Thermo Fisher Scientific, USA) was used to process the raw data obtained from the LC-S analysis. Each sample's data was normalized to total area. The sample number, normalized peak intensities, and all variate data (including retention time (rt) and charge-to-mass ratio (m/z)) were uploaded to SIMCA-P+ 12.0 software (Umetrics, Umea, Sweden). Multivariate analyses were performed to categorize the lipid samples; this included orthogonal partial least squares discriminant analysis (OPLS-DA) and principal component analysis (PCA). A permutation test with the permutation number of 200 was used to validate the OPLS-DA models [22]. Using Lipid Search software (Thermo Fisher Scientific, USA), a qualitative analysis of the lipid metabolites was performed. The information collected included the type of lipids, chain length, and number of saturated bonds. The screening conditions for the potential lipid biomarkers were determined by the lipid metabolites in the OPLS-DA model having variable importance in the projection (VIP) scores > 1 and P values obtained from the t − test < 0.05.

2.8. Statistical Analysis

GraphPad Prism 7.0 was used to determine whether differences between groups were significantly different. For differences between two groups, an unpaired, two-sided Student's t-test was conducted, whereas, for three or more groups, a one-way ANOVA was used. Statistical significance is set as P < 0.05.

3. Results

To explore ATP9A's role in EV release in HEK293 cells, the location of ATP9A in the cells was examined. Using red fluorescent protein- (RFP-) tagged ATP9A (ATP9A-OV), it was noted that the location of ATP9A in the cells was accumulated primarily in intracellular vesicles (Figure 1).
Figure 1

ATP9A localizes to intracellular vesicles and the plasma membrane. (a) To investigate ATP9A localization, HEK293 cells overexpressing ATP9A-RFP were detected using confocal microscopy. (b) HEK293 cells overexpressing ATP9A-RFP were labeled with general cell membrane dye PKH67-green.

As ATP9A was detected at the plasma membrane and intracellular vesicles, reduced expression of ATP9A could affect ectosome or exosome release. Figure 2 demonstrates that the number of EVs emitted in ATP9A-KO (ATP9A knockout cells) was significantly greater than the number of EVs released by the ATP9A-OV and plv-NC groups. The ATP9A-OV group released the fewest EVs. These findings suggest that the observed increase in the number of EVs from ATP9A knockout cells is mainly caused by elevated secretion of exosomes.
Figure 2

The total number of EVs is significantly greater in ATP9A knockdown cells. (a) EV secretion was evaluated in ATP9A knockdown (ATP9A-KO), ATP9A overexpression (ATP9A-OV), and plv-NC cells. (b) Exosome preparation was positive for exosome markers CD9, TSG101, and Alix and negative for ER marker calnexin. Tests were repeated in triplicate. ∗P < 0.05.

Lipidomics were performed for plv-NC, ATP9A-OV, and ATP9A-KO cells to better characterize the effects of ATP9A on exosome biosynthesis. Principal component analysis (PCA) showed that in the positive mode, the R2X and Q2 between the ATP9A-KO and plv-NC groups were 0.659 and -0.00879, respectively. Between the ATP9A-OV and plv-NC groups, the R2X and Q2 were 0.79 and 0.477, respectively. Finally, between the ATP9A-KO and ATP9A-OV groups, the R2X and Q2 values were 0.689 and 0.0479, respectively (Figure 3). As the R2X values all exceeded 0.4, the models were considered reliable. The PCA score plots obtained by comparing the three groups revealed that three clusters were separated in the positive mode by the first two components.
Figure 3

The PCA analysis of lipids in the plv-NC, ATP9A-OV, and ATP9A-KO groups. The PCA score plots obtained by comparing the three groups showed that three clusters were separated in the positive mode by the first two components. (a) PCA score between the plv-NC and ATP9A-KO groups. (b) PCA score between the plv-NC and ATP9A-OV groups. (c) PCA score between the ATP9A-KO and ATP9A-OV groups.

Figure 4 presents the PLS-DA score plots for the comparison of the three groups. This clearly shows separation in positive mode. The respective R2X, R2Y, and Q2 between the ATP9A-KO and plv-NC groups were 0.615, 0.983, and 0.851. Similarly, the respective R2X, R2Y, and Q2 values between the ATP9A-OV and plv-NC groups were 0.783, 0.99, and 0.951. Finally, the same respective values between the ATP9A-KO and ATP9A-OV groups were 0.539, 0.98, and 0.676.
Figure 4

The OPLS-DA score plots of the plv-NC, ATP9A-OV, and ATP9A-KO groups. (a) OPLS-DA score between the plv-NC and ATP9A-KO groups. (b) OPLS-DA score between the plv-NC and ATP9A-OV groups. (c) OPLS-DA score between the ATP9A-KO and ATP9A-OV groups.

Figure 5 presents the amount of different lipids as a percentage of the total. The percentage of Cer was significantly greater in the plv-NC group than in the ATP9A-OV and ATP9A-KO groups (P < 0.05). The level of sphingosine (So) was greatest in the plv-NC group (P < 0.05).
Figure 5

Percentage of all classes of lipids detected in the plv-NC, ATP9A-OV, and ATP9A-KO groups. Ceramides, lysophosphatidylcholine, phosphatidylglycerol, sphingomyelin, and triglycerides were the most common types of lipids. The percentage of ceramides (Cer), diacylglycerol (DG), lysophosphatidylcholine (LPC), lysophosphatidylmethanol (LPMe), monoglyceride (MG), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), sphingomyelin (SM), sphingoshine (So), and triglyceride (TG) are shown.

In total, there was a difference of 7 lipid classes, comprising 49 significantly different lipid metabolites, between the ATP9A-KO and plv-NC groups. This difference increased to 8 lipid classes and 137 significantly different lipid metabolites between the ATP9A-OV and plv-NC groups. The ATP9A-KO and ATP9A-OV groups differed by 5 lipid classes and 10 significantly different lipid metabolites (Table 1). The detailed differences in lipid metabolites between the plv-NC, ATP9A-KO, and ATP9A-OV groups in the positive mode are shown in Tables 2, 3, and 4. Table 5 shows the detailed differences in lipid metabolites between the ATP9A-OV and plv-NC groups in negative mode.
Table 1

The different lipid metabolites between the plv-NC, ATP9A-KO, and ATP9A-OV groups.

Lipid classATP9A-KO and plv-NCATP9A-OV and plv-NCATP9A-KO and ATP9A-OV
Positive modeNegative modeTotalPositive modeNegative modeTotalPositive modeNegative modeTotal
Phosphatidylcholine (PC)66164200
Phosphatidylethanolamine (PE)223322
Phosphatidylglycerol (PG)1100
Lysophosphatidylcholine (LPC)881211344
Phosphatidylinositol (Pl)0022
Triglyceride (TG)212187870
Diacylglycerol (DG)01111
Monogalactosylmonoacylglycerol (MGDG)0110
Sphingoshine (So)11220
Ceramides (Cer)1010101011
Total494913161371010
Table 2

Detailed differences in lipid metabolites between the ATP9A-KO and plv-NC groups in positive mode.

No.Lipid ionLipid groupClassFatty acidIon formulaVIP T-testLog_FC (ATP9a-KO/plv-NC)
1Cer(d20 : 0/18 : 0) + HCer(d38 : 0) + HCer(d20 : 0/18 : 0)C38 H78 O3 N11.26040.030618969-3.831098851
2Cer(d22 : 0/18 : 0) + HCer(d40 : 0) + HCer(d22 : 0/18 : 0)C40 H82 O3 N11.242350.025143001-4.328152705
3Cer(d28 : 0) + HCer(d28 : 0) + HCer(d28 : 0)C28 H58 O3 N11.281020.0294742-4.24959194
4Cer(d30 : 0) + HCer(d30 : 0) + HCer(d30 : 0)C30 H62 O3 N11.2750.025176996-3.979850415
5Cer(d32 : 0) + HCer(d32 : 0) + HCer(d32 : 0)C32 H66 O3 N11.266610.023622931-4.490550701
6Cer(d34 : 0) + HCer(d34 : 0) + HCer(d34 : 0)C34 H70 O3 N11.256720.029461839-4.056379416
7Cer(d34 : 0) + HCer(d34 : 0) + HCer(d34 : 0)C34 H70 O3 N11.230120.04426622-3.117818449
8Cer(d36 : 0) + HCer(d36 : 0) + HCer(d36 : 0)C36 H74 O3 N11.349940.008080528-4.472595341
9Cer(d36 : 3) + HCer(d36 : 3) + HCer(d36 : 3)C36 H68 O3 N11.299060.015827678-4.504241793
10Cer(d38 : 1) + HCer(d38 : 1) + HCer(d38 : 1)C38 H76 O3 N11.36650.004044369-4.339760529
11LPC(16 : 0) + HLPC(16 : 0) + HLPC(16 : 0)C24 H51 O7 N1 P11.196260.044904373-3.965795361
12LPC(16 : 0) + NaLPC(16 : 0) + NaLPC(16 : 0)C24 H50 O7 N1 P1 Na11.27190.019244897-4.12685101
13LPC(16 : 1) + HLPC(16 : 1) + HLPC(16 : 1)C24 H49 O7 N1 P11.379990.002239195-4.666120577
14LPC(18 : 1) + HLPC(18 : 1) + HLPC(18 : 1)C26 H53 O7 N1 P11.271080.019255048-3.993299768
15LPC(18 : 1) + HLPC(18 : 1) + HLPC(18 : 1)C26 H53 O7 N1 P11.271930.022622097-5.420039555
16LPC(18 : 3) + HLPC(18 : 3) + HLPC(18 : 3)C26 H49 O7 N1 P11.217830.033842529-3.871958979
17LPC(20 : 4) + HLPC(20 : 4) + HLPC(20 : 4)C28 H51 O7 N1 P11.30280.013961964-5.206227559
18LPC(22 : 6) + HLPC(22 : 6) + HLPC(22 : 6)C30 H51 O7 N1 P11.266020.021855354-4.887480292
19PC(31 : 0) + HPC(31 : 0) + HPC(31 : 0)C39 H79 O8 N1 P11.250340.043489185-2.736580322
20PC(33 : 0e) + HPC(33 : 0e) + HPC(33 : 0e)C41 H85 O7 N1 P11.242960.034649083-4.296299639
21PC(36 : 3) + HPC(36 : 3) + HPC(36 : 3)C44 H83 O8 N1 P11.258280.026138449-2.824548745
22PC(36 : 3) + HPC(36 : 3) + HPC(36 : 3)C44 H83 O8 N1 P11.221970.043015998-2.834383398
23PC(38 : 5) + HPC(38 : 5) + HPC(38 : 5)C46 H83 O8 N1 P11.264170.032636589-2.865997476
24PC(38 : 6) + HPC(38 : 6) + HPC(38 : 6)C46 H81 O8 N1 P11.25390.034802661-2.826696561
25PE(34 : 1e) + NaPE(34 : 1e) + NaPE(34:1e)C39 H78 O7 N1 P1 Na11.242960.034649083-4.296299639
26PE(38 : 6) + HPE(38 : 6) + HPE(38 : 6)C43 H75 O8 N1 P11.317510.016479104-4.448539426
27PG(45 : 6) + NH4PG(45 : 6) + NH4PG(45 : 6)C51 H93 O10 N1 P11.242960.034649083-4.296299639
28So(d16 : 0) + HSo(d16 : 0) + HSo(d16 : 0)C16 H36 O2 N11.257090.02502734-2.937662223
29TG(15 : 0/14 : 0/14 : 1) + NH4TG(43 : 1) + NH4TG(15 : 0/14 : 0/14 : 1)C46 H90 O6 N11.287540.026596333-0.398603466
30TG(15 : 0/17 : 0/17 : 0) + NH4TG(49 : 0) + NH4TG(15 : 0/17 : 0/17 : 0)C52 H104 O6 N11.37760.0031683-2.264427759
31TG(16 : 0/16 : 1/16 : 1) + NH4TG(48 : 2) + NH4TG(16 : 0/16 : 1/16 : 1)C51 H98 O6 N11.249660.034179356-4.494068391
32TG(16 : 0/18 : 1/18 : 1) + NH4TG(52 : 2) + NH4TG(16 : 0/18 : 1/18 : 1)C55 H106 O6 N11.271190.024617268-2.876897982
33TG(16 : 0/18 : 1/18 : 1) + NH4TG(52 : 2) + NH4TG(16 : 0/18 : 1/18 : 1)C55 H106 O6 N11.242730.029055366-5.502551812
34TG(16 : 1/16 : 1/16 : 1) + NH4TG(48 : 3) + NH4TG(16 : 1/16 : 1/16 : 1)C51 H96 O6 N11.250740.037153469-2.820151763
35TG(16 : 1/16 : 1/18 : 1) + NaTG(50 : 3) + NaTG(16 : 1/16 : 1/18 : 1)C53 H96 O6 Na11.382310.001565792-4.888822805
36TG(16 : 1/16 : 1/18 : 1) + NH4TG(50 : 3) + NH4TG(16 : 1/16 : 1/18 : 1)C53 H100 O6 N11.294880.013430777-4.189332374
37TG(16 : 1/18 : 1/18 : 1) + NaTG(52 : 3) + NaTG(16 : 1/18 : 1/18 : 1)C55 H100 O6 Na11.317660.013435952-3.30410743
38TG(16 : 1/18 : 1/18 : 1) + NH4TG(52 : 3) + NH4TG(16 : 1/18 : 1/18 : 1)C55 H104 O6 N11.309960.013226079-3.528809232
39TG(18 : 0/17 : 0/18 : 1) + NH4TG(53 : 1) + NH4TG(18 : 0/17 : 0/18 : 1)C56 H110 O6 N11.295980.0228725730.90918934
40TG(18 : 1/18 : 1/18 : 2) + NH4TG(54 : 4) + NH4TG(18 : 1/18 : 1/18 : 2)C57 H106 O6 N11.24320.044586752-5.336667642
41TG(18 : 1/18 : 2/18 : 2) + NH4TG(54 : 5) + NH4TG(18 : 1/18 : 2/18 : 2)C57 H104 O6 N11.24380.043561191-2.874871415
42TG(18 : 2/18 : 2/18 : 2) + NaTG(54 : 6) + NaTG(18 : 2/18 : 2/18 : 2)C57 H98 O6 Na11.289030.026337165-4.660675027
43TG(18 : 2/18 : 2/18 : 2) + NH4TG(54 : 6) + NH4TG(18 : 2/18 : 2/18 : 2)C57 H102 O6 N11.220840.039362783-4.36954712
44TG(18 : 4/18 : 1/18 : 1) + HTG(54 : 6) + HTG(18 : 4/18 : 1/18 : 1)C57 H99 O61.216030.04656314-3.727194618
45TG(20 : 5/18 : 2/18 : 2) + HTG(56 : 9) + HTG(20 : 5/18 : 2/18 : 2)C59 H97 O61.344120.00940743-5.064000583
46TG(4 : 0/16 : 0/18 : 0) + NH4TG(38 : 0) + NH4TG(4 : 0/16 : 0/18 : 0)C41 H82 O6 N11.302110.020072444-0.008648167
47TG(4 : 0/18 : 0/18 : 0) + NH4TG(40 : 0) + NH4TG(4 : 0/18 : 0/18 : 0)C43 H86 O6 N11.392320.001247294-1.058028038
48TG(6 : 0/16 : 0/20 : 4) + HTG(42 : 4) + HTG(6 : 0/16 : 0/20 : 4)C45 H79 O61.362810.0054190134.422086595
49TG(6 : 0/18 : 1/18 : 1) + NH4TG(42 : 2) + NH4TG(6 : 0/18 : 1/18 : 1)C45 H86 O6 N11.240280.04725919218.15651265
Table 3

Detailed differences in lipid metabolites between the ATP9A-KO and plv-NC groups in positive mode.

No.Lipid ionLipid groupClassFatty acidIon formulaVIP T-testLog_FC(ATP9a-OV/plv-NC)
1Cer(d20 : 0/18 : 0) + HCer(d38 : 0) + HCer(d20 : 0/18 : 0)C38 H78 O3 N11.180560.011353875-0.412362667
2Cer(d22 : 0/18 : 0) + HCer(d40 : 0) + HCer(d22 : 0/18 : 0)C40 H82 O3 N11.154780.017086722-0.595999589
3Cer(d22 : 1/2 : 0) + HCer(d24 : 1) + HCer(d22 : 1/2 : 0)C24 H48 O3 N11.118260.043499783-0.570814243
4Cer(d30 : 0) + HCer(d30 : 0) + HCer(d30 : 0)C30 H62 O3 N11.150350.025673707-0.586615549
5Cer(d32 : 0) + HCer(d32 : 0) + HCer(d32 : 0)C32 H66 O3 N11.107750.043725597-0.631568883
6Cer(d32 : 0) + HCer(d32 : 0) + HCer(d32 : 0)C32 H66 O3 N11.112140.048398875-0.841046781
7Cer(d32 : 0) + HCer(d32 : 0) + HCer(d32 : 0)C32 H66 O3 N11.134230.041166313-0.537395468
8Cer(d34 : 0) + HCer(d34 : 0) + HCer(d34 : 0)C34 H70 O3 N11.151750.021192786-0.739156196
9Cer(d36 : 0) + HCer(d36 : 0) + HCer(d36 : 0)C36 H74 O3 N11.15460.028080187-0.343491384
10Cer(d38 : 1) + HCer(d38 : 1) + HCer(d38 : 1)C38 H76 O3 N11.251480.000869044-0.708510594
11DG(18 : 1/18 : 1) + NH4DG(36 : 2) + NH4DG(18 : 1/18 : 1)C39 H76 O5 N11.147750.032034195-1.170941291
12LPC(14 : 0) + HLPC(14 : 0) + HLPC(14 : 0)C22 H47 O7 N1 P11.174920.011401697-2.037925913
13LPC(16 : 0) + HLPC(16 : 0) + HLPC(16 : 0)C24 H51 O7 N1 P11.183610.015200139-1.185399006
14LPC(16 : 0) + HLPC(16 : 0) + HLPC(16 : 0)C24 H51 O7 N1 P11.167220.016014207-1.586333123
15LPC(16 : 0) + NaLPC(16 : 0) + NaLPC(16 : 0)C24 H50 O7 N1 P1 Na11.20070.006996003-1.69267157
16LPC(16 : 1) + HLPC(16 : 1) + HLPC(16 : 1)C24 H49 O7 N1 P11.255010.000734215-1.973182318
17LPC(18 : 0) + HLPC(18 : 0) + HLPC(18 : 0)C26 H55 O7 N1 P11.176290.009004989-1.955935386
18LPC(18 : 1) + HLPC(18 : 1) + HLPC(18 : 1)C26 H53 O7 N1 P11.192390.008904148-1.722036886
19LPC(18 : 1) + HLPC(18 : 1) + HLPC(18 : 1)C26 H53 O7 N1 P11.178630.013931838-1.295055719
20LPC(18 : 2) + HLPC(18 : 2) + HLPC(18 : 2)C26 H51 O7 N1 P11.099750.033368835-1.836675727
21LPC(18 : 3) + HLPC(18 : 3) + HLPC(18 : 3)C26 H49 O7 N1 P11.175360.011863232-1.692803017
22LPC(20 : 4) + HLPC(20 : 4) + HLPC(20 : 4)C28 H51 O7 N1 P11.209890.006643335-1.601519506
23LPC(22 : 6) + HLPC(22 : 6) + HLPC(22 : 6)C30 H51 O7 N1 P11.181090.012416167-1.660861569
24PC(16 : 0/20 : 4) + NaPC(36 : 4) + NaPC(16 : 0/20 : 4)C44 H80 O8 N1 P1 Na11.187280.009695918-1.197287937
25PC(18 : 0/20 : 4) + NaPC(38 : 4) + NaPC(18 : 0/20 : 4)C46 H84 O8 N1 P1 Na11.193730.01387346-1.252308071
26PC(34 : 2) + HPC(34 : 2) + HPC(34 : 2)C42 H81 O8 N1 P11.131450.021697615-1.645003452
27PC(34 : 2) + NaPC(34 : 2) + NaPC(34 : 2)C42 H80 O8 N1 P1 Na11.142730.022076089-2.192884674
28PC(36 : 2) + HPC(36 : 2) + HPC(36 : 2)C44 H85 O8 N1 P11.186370.009290191-1.520413569
29PC(36 : 3) + HPC(36 : 3) + HPC(36 : 3)C44 H83 O8 N1 P11.20340.00592586-1.534810921
30PC(36 : 3) + HPC(36 : 3) + HPC(36 : 3)C44 H83 O8 N1 P11.0910.063303852-0.584433881
31PC(36 : 3) + HPC(36 : 3) + HPC(36 : 3)C44 H83 O8 N1 P11.177190.013773598-1.530770278
32PC(36 : 4) + HPC(36 : 4) + HPC(36 : 4)C44 H81 O8 N1 P11.152910.019974882-1.409087872
33PC(36 : 4) + HPC(36 : 4) + HPC(16 : 0/20 : 4)C44 H81 O8 N1 P11.150560.024222573-1.151908928
34PC(36 : 4p) + HPC(36 : 4p) + HPC(36 : 4p)C44 H81 O7 N1 P11.096670.056620135-1.032394903
35PC(38 : 4) + HPC(38 : 4) + HPC(18 : 0/20 : 4)C46 H85 O8 N1 P11.018350.138748412-0.52148975
36PC(38 : 5) + HPC(38 : 5) + HPC(38 : 5)C46 H83 O8 N1 P11.109150.058086289-0.647388207
37PC(38 : 6) + HPC(38 : 6) + HPC(38 : 6)C46 H81 O8 N1 P11.220930.004912756-1.089933633
38PC(38 : 6) + NaPC(38 : 6) + NaPC(38 : 6)C46 H80 O8 N1 P1 Na11.169890.018637803-1.222573329
39PC(40 : 7) + HPC(40 : 7) + HPC(40 : 7)C48 H83 O8 N1 P11.111130.053579975-0.945260739
40PE(16 : 0p/18 : 1) + HPE(34 : 1p) + HPE(16 : 0p/18 : 1)C39 H77 O7 N1 P11.110380.0553272790.456373702
41PE(38 : 6) + HPE(38 : 6) + HPE(38 : 6)C43 H75 O8 N1 P11.226390.004954273-2.282070421
42PE(39 : 5) + HPE(39 : 5) + HPE(39 : 5)C44 H79 O8 N1 P11.14430.017276536-1.751279845
43So(d14 : 1) + HSo(d14:1) + HSo(d14 : 1)C14 H30 O2 N11.171660.01993559-2.081806693
44So(d16 : 0) + HSo(d16 : 0) + HSo(d16 : 0)C16 H36 O2 N11.097330.046617899-1.916789565
45TG(12 : 0/12 : 0/18 : 3) + HTG(42 : 3) + HTG(12 : 0/12 : 0/18 : 3)C45 H81 O61.25580.0006769471.943382457
46TG(15 : 0/14 : 0/14 : 1) + NH4TG(43 : 1) + NH4TG(15 : 0/14 : 0/14 : 1)C46 H90 O6 N11.190990.0142291581.640598605
47TG(15 : 0/16 : 0/16 : 0) + NaTG(47 : 0) + NaTG(15 : 0/16 : 0/16 : 0)C50 H96 O6 Na11.13580.021424491.159764763
48TG(15 : 0/16 : 0/16 : 1) + NH4TG(47 : 1) + NH4TG(15 : 0/16 : 0/16 : 1)C50 H98 O6 N11.038270.099079456-0.913642961
49TG(15 : 0/16 : 0/18 : 1) + NH4TG(49 : 1) + NH4TG(15 : 0/16 : 0/18 : 1)C52 H102 O6 N11.176720.0170137430.731184335
50TG(15 : 0/17 : 0/17 : 0) + NH4TG(49 : 0) + NH4TG(15 : 0/17 : 0/17 : 0)C52 H104 O6 N11.168070.0222199371.500799668
51TG(15 : 1/14 : 0/16 : 1) + NH4TG(45 : 2) + NH4TG(15 : 1/14 : 0/16 : 1)C48 H92 O6 N11.126380.0464106621.228411695
52TG(16 : 0/10 : 0/18 : 1) + NH4TG(44 : 1) + NH4TG(16 : 0/10 : 0/18 : 1)C47 H92 O6 N11.214730.0065705631.270938382
53TG(16 : 0/12 : 0/13 : 0) + NH4TG(41 : 0) + NH4TG(16 : 0/12 : 0/13 : 0)C44 H88 O6 N11.218370.0061654091.937202801
54TG(16 : 0/12 : 0/14 : 0) + NaTG(42 : 0) + NaTG(16 : 0/12 : 0/14 : 0)C45 H86 O6 Na11.205580.009331991.253529015
55TG(16 : 0/12 : 0/14 : 0) + NH4TG(42 : 0) + NH4TG(16 : 0/12 : 0/14 : 0)C45 H90 O6 N11.124690.0414486840.995570056
56TG(16 : 0/12 : 0/18 : 1) + NH4TG(46 : 1) + NH4TG(16 : 0/12 : 0/18 : 1)C49 H96 O6 N11.219270.0062687950.851464834
57TG(16 : 0/13 : 0/14 : 0) + NH4TG(43 : 0) + NH4TG(16 : 0/13 : 0/14 : 0)C46 H92 O6 N11.117570.0454892131.347749132
58TG(16 : 0/14 : 0/14 : 0) + NaTG(44 : 0) + NaTG(16 : 0/14 : 0/14 : 0)C47 H90 O6 Na11.248050.0014989921.376050197
59TG(16 : 0/14 : 0/14 : 0) + NH4TG(44 : 0) + NH4TG(16 : 0/14 : 0/14 : 0)C47 H94 O6 N11.262370.0003531430.962131291
60TG(16 : 0/14 : 0/16 : 0) + NaTG(46 : 0) + NaTG(16 : 0/14 : 0/16 : 0)C49 H94 O6 Na11.268578.80516E-051.565797115
61TG(16 : 0/14 : 0/16 : 0) + NH4TG(46 : 0) + NH4TG(16 : 0/14 : 0/16 : 0)C49 H98 O6 N11.219010.006358891.450016601
62TG(16 : 0/14 : 0/20 : 4) + HTG(50 : 4) + HTG(16 : 0/14 : 0/20 : 4)C53 H95 O61.268549.83824E-051.326744372
63TG(16 : 0/16 : 0/16 : 0) + NaTG(48 : 0) + NaTG(16 : 0/16 : 0/16 : 0)C51 H98 O6 Na11.267080.0001305391.471325066
64TG(16 : 0/16 : 0/16 : 0) + NH4TG(48 : 0) + NH4TG(16 : 0/16 : 0/16 : 0)C51 H102 O6 N11.259720.0004207931.491554693
65TG(16 : 0/16 : 0/16 : 1) + NaTG(48 : 1) + NaTG(16 : 0/16 : 0/16 : 1)C51 H96 O6 Na11.269976.14983E-051.144805299
66TG(16 : 0/16 : 0/16 : 1) + NH4TG(48 : 1) + NH4TG(16 : 0/16 : 0/16 : 1)C51 H100 O6 N11.254630.0008977871.053045297
67TG(16 : 0/16 : 0/18 : 1) + NaTG(50 : 1) + NaTG(16 : 0/16 : 0/18 : 1)C53 H100 O6 Na11.250280.001065831.831200518
68TG(16 : 0/16 : 0/18 : 1) + NH4TG(50 : 1) + NH4TG(16 : 0/16 : 0/18 : 1)C53 H104 O6 N11.251920.0007715751.773752236
69TG(16 : 0/16 : 0/20 : 3) + HTG(52 : 3) + HTG(16 : 0/16 : 0/20 : 3)C55 H101 O61.267340.0001207462.280590338
70TG(16 : 0/16 : 0/20 : 4) + HTG(52 : 4) + HTG(16 : 0/16 : 0/20 : 4)C55 H99 O61.250010.0011634771.849719348
71TG(16 : 0/16 : 1/18 : 1) + NaTG(50 : 2) + NaTG(16 : 0/16 : 1/18 : 1)C53 H98 O6 Na11.039020.051199679-0.248516244
72TG(16 : 0/17 : 0/18 : 1) + NH4TG(51 : 1) + NH4TG(16 : 0/17 : 0/18 : 1)C54 H106 O6 N11.128840.0428027342.648612904
73TG(16 : 0/18 : 1/18 : 1) + NH4TG(52 : 2) + NH4TG(16 : 0/18 : 1/18 : 1)C55 H106 O6 N11.045510.102202776-1.220332232
74TG(16 : 0/18 : 2/18 : 2) + NaTG(52 : 4) + NaTG(16 : 0/18 : 2/18 : 2)C55 H98 O6 Na11.012760.072197269-0.233717192
75TG(16 : 0/18 : 2/18 : 2) + NH4TG(52 : 4) + NH4TG(16 : 0/18 : 2/18 : 2)C55 H102 O6 N11.15790.015560565-0.777716804
76TG(16 : 0/8 : 0/18 : 1) + NH4TG(42 : 1) + NH4TG(16 : 0/8 : 0/18 : 1)C45 H88 O6 N11.273725.23657E-062.89136082
77TG(16 : 1/16 : 1/18 : 1) + NaTG(50 : 3) + NaTG(16 : 1/16 : 1/18 : 1)C53 H96 O6 Na11.248880.000976709-0.791307191
78TG(16 : 1/16 : 1/18 : 1) + NH4TG(50 : 3) + NH4TG(16 : 1/16 : 1/18 : 1)C53 H100 O6 N11.169960.013073421-0.641262818
79TG(16 : 1/18 : 1/18 : 1) + NaTG(52 : 3) + NaTG(16 : 1/18 : 1/18 : 1)C55 H100 O6 Na11.227480.002533394-0.763755159
80TG(16 : 1/18 : 1/18 : 1) + NH4TG(52 : 3) + NH4TG(16 : 1/18 : 1/18 : 1)C55 H104 O6 N11.201620.005474227-0.786386257
81TG(18 : 0/16 : 0/16 : 0) + NaTG(50 : 0) + NaTG(18 : 0/16 : 0/16 : 0)C53 H102 O6 Na11.266140.0001588372.275169817
82TG(18 : 0/16 : 0/16 : 0) + NH4TG(50 : 0) + NH4TG(18 : 0/16 : 0/16 : 0)C53 H106 O6 N11.262930.0002813142.032336625
83TG(18 : 0/16 : 0/18 : 0) + NaTG(52 : 0) + NaTG(18 : 0/16 : 0/18 : 0)C55 H106 O6 Na11.259220.0005206212.41337606
84TG(18 : 0/16 : 0/18 : 0) + NH4TG(52 : 0) + NH4TG(18 : 0/16 : 0/18 : 0)C55 H110 O6 N11.265970.0001809152.667777604
85TG(18 : 0/16 : 0/18 : 1) + NaTG(52 : 1) + NaTG(18 : 0/16 : 0/18 : 1)C55 H104 O6 Na11.267240.0001385322.887231449
86TG(18 : 0/16 : 0/18 : 1) + NH4TG(52 : 1) + NH4TG(18 : 0/16 : 0/18 : 1)C55 H108 O6 N11.260450.0004620913.231733656
87TG(18 : 0/16 : 0/20 : 4) + HTG(54 : 4) + HTG(18 : 0/16 : 0/20 : 4)C57 H103 O61.267690.0001241793.110340992
88TG(18 : 0/16 : 0/22 : 0) + NH4TG(56 : 0) + NH4TG(18 : 0/16 : 0/22 : 0)C59 H118 O6 N11.229680.0043166662.187805394
89TG(18 : 0/17 : 0/18 : 0) + NH4TG(53 : 0) + NH4TG(18 : 0/17 : 0/18 : 0)C56 H112 O6 N11.261380.0003969042.424298519
90TG(18 : 0/17 : 0/18 : 1) + NH4TG(53 : 1) + NH4TG(18 : 0/17 : 0/18 : 1)C56 H110 O6 N11.186020.0166644372.713496047
91TG(18 : 0/18 : 0/18 : 0) + NaTG(54 : 0) + NaTG(18 : 0/18 : 0/18 : 0)C57 H110 O6 Na11.268270.0001052235.230250311
92TG(18 : 0/18 : 0/18 : 0) + NH4TG(54 : 0) + NH4TG(18 : 0/18 : 0/18 : 0)C57 H114 O6 N11.269495.7205E-052.285459979
93TG(18 : 0/18 : 0/18 : 1) + NaTG(54 : 1) + NaTG(18 : 0/18 : 0/18 : 1)C57 H108 O6 Na11.262780.0003054864.481228399
94TG(18 : 0/18 : 0/18 : 1) + NH4TG(54 : 1) + NH4TG(18 : 0/18 : 0/18 : 1)C57 H112 O6 N11.271433.13706E-054.649314869
95TG(18 : 0/18 : 0/18 : 3) + HTG(54 : 3) + HTG(18 : 0/18 : 0/18 : 3)C57 H105 O61.261980.0003569752.416341259
96TG(18 : 0/18 : 0/20 : 4) + HTG(56 : 4) + HTG(18 : 0/18 : 0/20 : 4)C59 H107 O61.262730.0003078054.483895814
97TG(18 : 0/18 : 1/18 : 1) + NaTG(54 : 2) + NaTG(18 : 0/18 : 1/18 : 1)C57 H106 O6 Na11.226340.0027280951.662501
98TG(18 : 0/18 : 1/18 : 1) + NH4TG(54 : 2) + NH4TG(18 : 0/18 : 1/18 : 1)C57 H110 O6 N11.196340.0100410251.513228258
99TG(18 : 1/18 : 1/18 : 2) + NH4TG(54 : 4) + NH4TG(18 : 1/18 : 1/18 : 2)C57 H106 O6 N11.155880.023234959-0.351349117
100TG(18 : 1/18 : 1/20 : 4) + HTG(56 : 6) + HTG(18 : 1/18 : 1/20 : 4)C59 H103 O61.040170.05964527-0.182813869
101TG(18 : 1/18 : 2/18 : 2) + NH4TG(54 : 5) + NH4TG(18 : 1/18 : 2/18 : 2)C57 H104 O6 N11.225170.004865563-0.471280945
102TG(18 : 2/18 : 2/18 : 2) + NaTG(54 : 6) + NaTG(18 : 2/18 : 2/18 : 2)C57 H98 O6 Na11.019990.138715238-0.381333699
103TG(18 : 2/18 : 2/18 : 2) + NH4TG(54 : 6) + NH4TG(18 : 2/18 : 2/18 : 2)C57 H102 O6 N11.142380.030646745-0.792226116
104TG(18 : 3/18 : 2/18 : 2) + HTG(54 : 7) + HTG(18 : 3/18 : 2/18 : 2)C57 H97 O61.08530.053095571-0.233717192
105TG(18 : 3/18 : 2/18 : 2) + NH4TG(54 : 7) + NH4TG(18 : 3/18 : 2/18 : 2)C57 H100 O6 N11.046340.083166907-0.934006022
106TG(18 : 4/18 : 1/18 : 1) + HTG(54 : 6) + HTG(18 : 4/18 : 1/18 : 1)C57 H99 O61.176090.009589781-0.65252347
107TG(20 : 0e/18 : 2/18 : 3) + HTG(56 : 5e) + HTG(20 : 0e/18 : 2/18 : 3)C59 H107 O51.204620.0100602863.325380766
108TG(20 : 5/18 : 2/18 : 2) + HTG(56 : 9) + HTG(20 : 5/18 : 2/18 : 2)C59 H97 O61.014990.144587695-0.440537678
109TG(4 : 0/12 : 0/18 : 1) + NH4TG(34 : 1) + NH4TG(4 : 0/12 : 0/18 : 1)C37 H72 O6 N11.202960.010367024.04828539
110TG(4 : 0/12 : 0/18 : 3) + HTG(34 : 3) + HTG(4 : 0/12 : 0/18 : 3)C37 H65 O61.064750.0620649210.316304726
111TG(4 : 0/14 : 0/18 : 1) + NH4TG(36 : 1) + NH4TG(4 : 0/14 : 0/18 : 1)C39 H76 O6 N11.249760.00135097223.88325332
112TG(4 : 0/14 : 0/18 : 3) + HTG(36 : 3) + HTG(4 : 0/14 : 0/18 : 3)C39 H69 O61.143850.0350669232.573454618
113TG(4 : 0/15 : 0/16 : 0) + NH4TG(35 : 0) + NH4TG(4 : 0/15 : 0/16 : 0)C38 H76 O6 N11.267520.0001219815.017537183
114TG(4 : 0/15 : 0/18 : 1) + NH4TG(37 : 1) + NH4TG(4 : 0/15 : 0/18 : 1)C40 H78 O6 N11.20240.0108224763.978439339
115TG(4 : 0/16 : 0/17 : 0) + NH4TG(37 : 0) + NH4TG(4 : 0/16 : 0/17 : 0)C40 H80 O6 N11.260520.0004571053.907668532
116TG(4 : 0/16 : 0/18 : 0) + NaTG(38 : 0) + NaTG(4 : 0/16 : 0/18 : 0)C41 H78 O6 Na11.223450.0050854562.38625847
117TG(4 : 0/16 : 0/18 : 0) + NH4TG(38 : 0) + NH4TG(4 : 0/16 : 0/18 : 0)C41 H82 O6 N11.108350.0585708881.040201462
118TG(4 : 0/16 : 0/18 : 1) + NaTG(38 : 1) + NaTG(4 : 0/16 : 0/18 : 1)C41 H76 O6 Na11.253750.0009495166.971333525
119TG(4 : 0/16 : 0/18 : 1) + NH4TG(38 : 1) + NH4TG(4 : 0/16 : 0/18 : 1)C41 H80 O6 N11.250570.0012354316.528128518
120TG(4 : 0/16 : 0/20 : 3) + HTG(40 : 3) + HTG(4 : 0/16 : 0/20 : 3)C43 H77 O61.234890.0032495993.288156904
121TG(4 : 0/17 : 0/18 : 1) + NH4TG(39 : 1) + NH4TG(4 : 0/17 : 0/18 : 1)C42 H82 O6 N11.25270.0010622634.151115681
122TG(4 : 0/18 : 0/18 : 0) + NH4TG(40 : 0) + NH4TG(4 : 0/18 : 0/18 : 0)C43 H86 O6 N11.135290.0363234121.926228297
123TG(4 : 0/18 : 1/18 : 1) + NaTG(40 : 2) + NaTG(4 : 0/18 : 1/18 : 1)C43 H78 O6 Na11.227070.0044395941.831811125
124TG(4 : 0/18 : 1/18 : 1) + NH4TG(40 : 2) + NH4TG(4 : 0/18 : 1/18 : 1)C43 H82 O6 N11.227640.0042586071.648333529
125TG(4 : 0/18 : 1/18 : 3) + HTG(40 : 4) + HTG(4 : 0/18 : 1/18 : 3)C43 H75 O61.253750.0009495166.971333525
126TG(46 : 1) + NaTG(46 : 1) + NaTG(16 : 0/12 : 0/18 : 1)C49 H92 O6 Na11.239010.0027452570.902280507
127TG(6 : 0/16 : 0/17 : 0) + NH4TG(39 : 0) + NH4TG(6 : 0/16 : 0/17 : 0)C42 H84 O6 N11.256240.0007282652.333598845
128TG(6 : 0/16 : 0/18 : 1) + NH4TG(40 : 1) + NH4TG(6 : 0/16 : 0/18 : 1)C43 H84 O6 N11.268748.63677E-054.581376753
129TG(6 : 0/16 : 0/20 : 4) + HTG(42 : 4) + HTG(6 : 0/16 : 0/20 : 4)C45 H79 O61.261660.0003798437.405154525
130TG(6 : 0/18 : 1/18 : 1) + NH4TG(42 : 2) + NH4TG(6 : 0/18 : 1/18 : 1)C45 H86 O6 N11.244370.00193990219.65297904
131TG(8 : 0/12 : 0/18 : 3) + HTG(38 : 3) + HTG(8 : 0/12 : 0/18 : 3)C41 H73 O61.199760.0118852452.272770506
Table 4

Detailed differences in lipid metabolites between the ATP9A-OV and ATP9A-KO groups in positive mode.

No.Lipid ionLipid groupClassFatty acidIon formulaVIP T-testLog_FC(ATP9a-OV/ATP9a-KO)
1Cer(d32 : 0) + HCer(d32 : 0) + HCer(d32 : 0)C32 H66 O3 N11.534070.046202984-1.221196739
2DG(18 : 1/18 : 1) + NH4DG(36 : 2) + NH4DG(18 : 1/18 : 1)C39 H76 O5 N11.574890.033527384-0.844934869
3LPC(16 : 0) + HLPC(16 : 0) + HLPC(16 : 0)C24 H51 O7 N1 P11.556930.038858829-0.646114065
4LPC(16 : 1) + HLPC(16 : 1) + HLPC(16 : 1)C24 H49 O7 N1 P11.678840.010297907-0.870328703
5LPC(18 : 0) + HLPC(18 : 0) + HLPC(18 : 0)C26 H55 O7 N1 P11.573030.034060664-1.147680261
6LPC(20 : 4) + HLPC(20 : 4) + HLPC(20 : 4)C28 H51 O7 N1 P11.613950.023265476-0.549852755
7PE(16 : 0p/18 : 1) + HPE(34 : 1p) + HPE(16 : 0p/18 : 1)C39 H77 O7 N1 P11.646620.0160939191.531453663
8PE(38 : 6) + HPE(38 : 6) + HPE(38 : 6)C43 H75 O8 N1 P11.650570.015315495-0.898920166
9TG(15 : 0/16 : 0/16 : 0) + NaTG(47 : 0) + NaTG(15 : 0/16 : 0/16 : 0)C50 H96 O6 Na11.596470.0276312580.747616493
10TG(16 : 0/12 : 0/13 : 0) + NH4TG(41 : 0) + NH4TG(16 : 0/12 : 0/13 : 0)C44 H88 O6 N11.564160.0366678331.376598918
Table 5

Detailed differences in lipid metabolites between the ATP9A-OV and plv-NC groups in negative mode.

No.Lipid ionLipid groupClassFatty acidIon formulaVIP T-testLog_FC(ATP9A-OV/plv-NC)
1LPC(16 : 0) + HCOOLPC(16 : 0) + HCOOLPC(16 : 0)C25 H51 O9 N1 P11.426190.02839175-0.956682794
2PC(16 : 0/18 : 2) + HCOOPC(34 : 2) + HCOOPC(16 : 0/18 : 2)C43 H81 O10 N1 P11.408260.033403463-0.777315557
3PC(16 : 0/20 : 4) + HCOOPC(36 : 4) + HCOOPC(16 : 0/20 : 4)C45 H81 O10 N1 P11.452510.020556433-0.64073783
4PC(18 : 0/18 : 2) + HCOOPC(36 : 2) + HCOOPC(18 : 0/18 : 2)C45 H85 O10 N1 P11.48450.011801161-0.732314818
5PC(16 : 0/22 : 6) + HCOOPC(38 : 6) + HCOOPC(16 : 0/22 : 6)C47 H81 O10 N1 P11.383460.030681364-0.753866237
6MGDG(47 : 12) + HCOOMGDG(47 : 12) + HCOOMGDG(47 : 12)C57 H85 O121.528920.004986124-0.722153703

4. Discussion

ATP9A, a trafficking protein, plays a key role in the initiation of vesicle biogenesis [7, 23]. In this study, we found that the release of EVs from HEK293 cells was modulated by P4-ATPase ATP9A. The percentage of ceramides and sphingosine was significantly greater in the normal control cells than in the ATP9A overexpression and ATP9A knockout cells. The subcellular localization of mammalian P4-ATPases was observed using fluorescently labeled phospholipids to visualize the transport of phospholipids into cells. ATP9A was detected in the plasma membrane and intracellular compartments. This suggests that the presence of ATP9A in the plasma membrane is important for the purpose of assisting in the recycling of plasma membrane proteins through endocytosis [23]. EV release was increased in cell lines when ATP9A was knocked out; this implies that ATP9A plays an inhibitory role in EV release. Many biological processes, such as angiogenesis, blood clotting, and immune response, are modulated by proteins, DNA, miRNA, and mRNAs, which could be controlled via EV-instigated intercellular communication. In this study, we demonstrated that exosome secretion was inhibited by ATP9A and this could be achieved through glucose transporter 1 (GLUT1) and transferrin receptor, as they are recycled to the plasma membrane through ATP9A endocytic recycling [17]. The knockdown expression of ATP9A in human hepatoma cells shows that the elevated release of EVs is independent of the activation of caspase-3 [23]. The quantity of EVs was significantly reduced in ATP9A knockdown cells in which exosome release had been pharmacologically blocked [23]. It is also possible that the elevated secretion of EVs is secondary to disrupting other key processes. ATP9A deficiency may be associated with cell death, proliferation, and survival pathways. Indeed, in HepG2 cells in which ATP9A was minimal, the cells underwent massive cell death approximately two weeks after ATP9A had been exhausted. As mentioned previously, ATP9A is a member of subclass 2 in P4-ATPases [11]; Neo1 (Saccharomyces cerevisiae) and TAT-5 (C. elegans) are orthologs of ATP9A. While it is recognized that P4-ATPase deficiency can result in lethal consequences, it is not yet known what molecular mechanisms are responsible for this phenomenon [24]. Hela cells containing CRISPR-mediated knockout of ATP9A did not die; however, it is noted that data for long-term culture were omitted [17]. This suggests that some cell types can withstand ATP9A depletion; the pathway in which the protein is involved may determine the outcome. P4-ATPases are important to many plasma and intracellular membrane-associated processes. One of these enzymes' primary functions is to institute and maintain a state of phospholipid asymmetry of cell membranes [7]. Increased exposure of PS in the exoplasmic leaflet of ATP9A-depleted HepG2 cells resulted in partial loss of plasma membrane asymmetry [23]. In S. cerevisiae, the asymmetry of the plasma membrane is lost as PE and PS become exposed as a consequence of NEO1 deficiency [24]. Similarly, the exposure of PE in the exoplasmic leaflet of C. elegans increases with TAT-5 deficiency; however, no external PS was detected [16]. In this study, ATP9A-depleted HEK293 cells did not exhibit an increase in PS, but ceramides (Cer) and sphingosine were decreased in cells in which ATP9A was overexpressed or knocked out. A number of pathologies are associated with dysregulated sphingolipid metabolism; these include cancer, cardiovascular disease, hepatic steatosis, metabolic disorders, neurological disease, and type 2 diabetes [25, 26]. Exosomes were exchanged between the tumor cells and other tissues; however, few studies have examined the functional roles of these exosomal lipids [27]. Cer is enriched in the exosomes, and it is also an important lipid in exosomal formation. As the center in the sphingolipid metabolism, Cer is predominantly produced via acid sphingomyelinase-mediated hydrolysis of sphingomyelin and then metabolized to sphingosine by acid ceramidase [28]. Cosker and Segal suggested that the exosomal lipids can transmit “mobile rafts” that can activate cell signaling pathways in oncogenesis and metastasis [29]. Cer can modulate the roles of these mobile rafts and their effects on the signaling pathways [29]. Sphingosine may increase the activation of the TRPML1 channel in the presence of ML-SA1. ATP9A may regulate sphingosine production and, thus, decrease TRPML1 channel activity [30]. It was previously postulated that the translocation undertaken by P4-ATPases was selective, favoring glycerophospholipids and excluding sphingolipids. Thus, the molecular relationship between ATP9A and ceramides and sphingosine are mysterious [31].
  31 in total

Review 1.  Revisiting transbilayer distribution of lipids in the plasma membrane.

Authors:  Motohide Murate; Toshihide Kobayashi
Journal:  Chem Phys Lipids       Date:  2015-08-28       Impact factor: 3.329

Review 2.  Ectosomes and exosomes: shedding the confusion between extracellular vesicles.

Authors:  Emanuele Cocucci; Jacopo Meldolesi
Journal:  Trends Cell Biol       Date:  2015-02-12       Impact factor: 20.808

3.  The P4-ATPase TAT-5 inhibits the budding of extracellular vesicles in C. elegans embryos.

Authors:  Ann M Wehman; Corey Poggioli; Peter Schweinsberg; Barth D Grant; Jeremy Nance
Journal:  Curr Biol       Date:  2011-11-17       Impact factor: 10.834

4.  The Essential Neo1 Protein from Budding Yeast Plays a Role in Establishing Aminophospholipid Asymmetry of the Plasma Membrane.

Authors:  Mehmet Takar; Yuantai Wu; Todd R Graham
Journal:  J Biol Chem       Date:  2016-05-26       Impact factor: 5.157

5.  ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences.

Authors:  Yi-Nan Gong; Cliff Guy; Hannes Olauson; Jan Ulrich Becker; Mao Yang; Patrick Fitzgerald; Andreas Linkermann; Douglas R Green
Journal:  Cell       Date:  2017-04-06       Impact factor: 41.582

6.  Critical roles of isoleucine-364 and adjacent residues in a hydrophobic gate control of phospholipid transport by the mammalian P4-ATPase ATP8A2.

Authors:  Anna L Vestergaard; Jonathan A Coleman; Thomas Lemmin; Stine A Mikkelsen; Laurie L Molday; Bente Vilsen; Robert S Molday; Matteo Dal Peraro; Jens Peter Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

7.  The P4-ATPase ATP9A is a novel determinant of exosome release.

Authors:  Jyoti Naik; Chi M Hau; Lysbeth Ten Bloemendaal; Kam S Mok; Najat Hajji; Ann M Wehman; Sander Meisner; Vanesa Muncan; Nanne J Paauw; H E de Vries; Rienk Nieuwland; Coen C Paulusma; Piter J Bosma
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

Review 8.  P4-ATPases as Phospholipid Flippases-Structure, Function, and Enigmas.

Authors:  Jens P Andersen; Anna L Vestergaard; Stine A Mikkelsen; Louise S Mogensen; Madhavan Chalat; Robert S Molday
Journal:  Front Physiol       Date:  2016-07-08       Impact factor: 4.566

9.  Phosphatidylethanolamine dynamics are required for osteoclast fusion.

Authors:  Atsushi Irie; Kei Yamamoto; Yoshimi Miki; Makoto Murakami
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

10.  Growth and Lipidomic Responses of Juvenile Pacific White Shrimp Litopenaeus vannamei to Low Salinity.

Authors:  Maoxian Huang; Yangfan Dong; Yan Zhang; Qinsheng Chen; Jia Xie; Chang Xu; Qun Zhao; Erchao Li
Journal:  Front Physiol       Date:  2019-08-23       Impact factor: 4.566

View more
  2 in total

Review 1.  Engineering exosomes for targeted drug delivery.

Authors:  Yujie Liang; Li Duan; Jianping Lu; Jiang Xia
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

2.  Homozygosity Haplotype and Whole-Exome Sequencing Analysis to Identify Potentially Functional Rare Variants Involved in Multiple Sclerosis among Sardinian Families.

Authors:  Teresa Fazia; Daria Marzanati; Anna Laura Carotenuto; Ashley Beecham; Athena Hadjixenofontos; Jacob L McCauley; Valeria Saddi; Marialuisa Piras; Luisa Bernardinelli; Davide Gentilini
Journal:  Curr Issues Mol Biol       Date:  2021-10-27       Impact factor: 2.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.